ArticleAmerican journal of translational research2021
Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson's disease and depression.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Pooled it
- The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention.EBioMedicine · 2026Article
- Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.Brain and behavior · 2025Article
- The Face of Emotion: Botulinum Toxin, Emotional Anatomy, and Mood Modulation.Journal of cosmetic dermatology · 2025Review
- Botulinum neurotoxin A ameliorates depressive-like behavior in a reserpine-induced Parkinson's disease mouse model via suppressing hippocampal microglial engulfment and neuroinflammation.Acta pharmacologica Sinica · 2023Article
- Review
- Treatment of Depression with Botulinum Toxin.Toxins · 2022Review
- Comment on effects of botulinum toxin type A on mood and cognitive function in patients with Parkinson's disease and depression.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the effects of botulinum toxin type A (BtA) in the treatment of patients with Parkinson's disease and depression.
method89 patients with Parkinson's disease and depression were assigned into control group and observation group by random number table method, of which 44 patients in the control group were treated with sertraline and 45 patients in the observation group were treated with BtA. The two groups were compared in terms of mood, cognitive function and adverse reactions.
resultsThe Hamilton Depression Self-Assessment Scale (HAMD) scores of the two groups following treatment were lower than those before treatment while the Mini-Mental State Examination (MMSE) scores were higher than those before treatment (P<0.05). The incidence rate of adverse events was 11.11% in the observation group and 29.55% in the control group (
conclusionPatients with Parkinson's disease and depression receiving BtA treatment can gain treatment effects similar to those of the sertraline, with less adverse reactions.
Indexed as
Identifiers
34017433PMC8129423W3162578069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.